Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe.
Fraser H, Martin NK, Brummer-Korvenkontio H, Carrieri P, Dalgard O, Dillon J, Goldberg D, Hutchinson S, Jauffret-Roustide M, Kåberg M, Matser AA, Matičič M, Midgard H, Mravcik V, Øvrehus A, Prins M, Reimer J, Robaeys G, Schulte B, van Santen DK, Zimmermann R, Vickerman P, Hickman M
HIV and hepatitis C treatment uptake among people who use drugs participating in the Amsterdam Cohort Studies, 1985-2015.
van Santen DK, van der Helm JJ, Lindenburg K, Schim van der Loeff M, Prins M
Lack of decline in hepatitis C virus incidence among HIV-positive men who have sex with men during 1990-2014.
van Santen DK, van der Helm JJ, Del Amo J, Meyer L, D'Arminio Monforte A, Price M, Béguelin CA, Zangerle R, Sannes M, Porter K, Geskus RB, Prins M, CASCADE Collaboration in EuroCoord
The effect of HIV infection on anal and penile human papillomavirus incidence and clearance: a cohort study among MSM.
Mooij SH, van Santen DK, Geskus RB, van der Sande MA, Coutinho RA, Stolte IG, Snijders PJ, Meijer CJ, Speksnijder AG, de Vries HJ, King AJ, van Eeden A, van der Loeff MF
Cost-Effectiveness of Hepatitis C Treatment for People Who Inject Drugs and the Impact of the Type of Epidemic; Extrapolating from Amsterdam, the Netherlands.
van Santen DK, de Vos AS, Matser A, Willemse SB, Lindenburg K, Kretzschmar ME, Prins M, de Wit GA